Drugs / BAY1834942
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03596372 | Jun 2018 → Nov 2020 | — | Bayer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1834942 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03596372 ↗ |
| Known as | Tinurilimab | “A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.” PMID 40465170 ↗ Jun 2025 |